Abstract Details

Title Real-world Use of Deutetrabenazine Reduces Tardive Dyskinesia Severity and Improves Quality of Life: Patient-reported Outcomes in the IMPACT-TD Study

Topic Movement Disorders

Presentation(s) P7 - Poster Session 7 (8:00 AM-9:00 AM)

Poster/Presentation
Number 16-004

Objective To evaluate the real-world effectiveness of deutetrabenazine (DTBZ) treatment on the multidimensional impact of tardive dyskinesia (TD), as assessed by patient-reported outcome (PRO) scales.

Background TD can substantially impair quality of life, highlighting the need to assess the effect of treatment on PROs.

Design/Methods The IMPACT-TD Registry is an ongoing phase 4 study including 611 adults with a score of ≥2 on ≥1 item of the Abnormal Involuntary Movement Scale (AIMS) and probable TD or, alternatively, who were receiving vesicular monoamine transporter 2 (VMAT2) inhibitor therapy for TD at enrollment. Part B included participants who were naïve to VMAT2 inhibitor treatment or for whom ≥3 months had elapsed since VMAT2 inhibitor exposure and for whom DTBZ was prescribed per routine clinical care. At baseline and at monthly visits, participants completed the IMPACT-TD PRO scale and rated the severity of their TD and underlying psychiatric conditions with the Patient Global Impression of Severity (PGIS) scales (TD-specific, PGIS-TD and psychiatric-specific, PGIS-Psych).

Results Among 27 adults who initiated and completed 3 months of DTBZ treatment at this interim analysis (age range 26–80 years, 67% female, 63% White), all had ≥1 comorbid psychiatric disorder. At month 3, total motor AIMS score mean (SE) change from baseline was −2.9 (1.1). Participants with baseline impact reported meaningful improvements at month 3 in activities of daily living (59%), psychosocial impact (65%), eating (75%), speech/communication (77%), and sleep/pain (50%). At month 3, PGIS-TD was improved in 63% of participants and PGIS-Psych was improved/remained stable in 85% of participants.

Conclusions In this real-world study, IMPACT-TD Registry participants newly treated with DTBZ for TD had meaningful reductions in abnormal movement severity, similar to those seen in the pivotal randomized controlled trials. Up to 77% of participants experienced meaningful improvements in specific aspects of their lives impacted by TD.

Authors/Disclosures
Diana Klakotskaia PRESENTER	Diana Klakotskaia has received personal compensation for serving as an employee of Teva Pharmaceuticals. Diana Klakotskaia has stock in Teva Pharmaceuticals.
Stacy Finkbeiner	Stacy Finkbeiner has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Martijn Konings (Teva Pharmaceutical Inc.)	Martijn Konings has received personal compensation for serving as an employee of Teva Pharmaceuticals. Martijn Konings has stock in Teva Pharmaceuticals.
Mark Henegar, PharmD	Dr. Henegar has stock in Teva.
Daisy Yu, PhD	Dr. Yu has nothing to disclose.
Richard Jackson, MD	Dr. Jackson has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for teva. Dr. Jackson has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for teva . Dr. Jackson has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for teva.

��ɫ��

��ɫ��